266 related articles for article (PubMed ID: 24690243)
1. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
2. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
4. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
5. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.
Horn J; Lock-Andersen J; Sjøstrand H; Loft A
Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):887-92. PubMed ID: 16586078
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II.
Klode J; Dissemond J; Grabbe S; Hillen U; Poeppel T; Boeing C
Dermatol Surg; 2010 Apr; 36(4):439-45. PubMed ID: 20187901
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
9. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
Uren RF; Howman-Giles R; Chung D; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
[TBL] [Abstract][Full Text] [Related]
13. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
14. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.
Nieweg O; Valdés Olmos R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):602; author reply 603. PubMed ID: 17205347
[No Abstract] [Full Text] [Related]
15. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
[TBL] [Abstract][Full Text] [Related]
16. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
17. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
Macfarlane DJ; Sondak V; Johnson T; Wahl RL
J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890
[TBL] [Abstract][Full Text] [Related]
19. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
20. [PET scanning for malignant melanoma and positive sentinel node diagnostics].
Horn J; Sjøstrand H; Lock-Andersen J; Loft A
Ugeskr Laeger; 2010 Apr; 172(15):1126-30. PubMed ID: 20427004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]